Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
November 12, 2001
- Drug Cost Ratio Down to Record Low of 22.8%
November 12, 2001
- WORLD NEWS IN BRIEF
November 12, 2001
- BULLETIN
November 12, 2001
- DIAGNOSTIC NEWS IN BRIEF
November 12, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
November 12, 2001
- EFPIA Stresses That Reforms Are Needed to Promote Innovation
November 12, 2001
- Sankyo Planning Late PII Study on Pitavastatin in US
November 12, 2001
- REGULATORY NEWS IN BRIEF
November 5, 2001
- JABEX Calls For Policy to Make Japan Bioindustry-based Nation
November 5, 2001
- JPA Opposes Healthcare Cost Ceiling System
November 5, 2001
- Healthcare Services Incompatible with Market Economy: JMA Seminar
November 5, 2001
- Prozac, Evista to Boost Eli Lilly Japan to Enter Top 10 by 2010: President Mascarenhas
November 5, 2001
- JMA Presents Proposals for Financial Reconstruction of Health Insurance Programs
November 5, 2001
- J&J to Buy Out Kyowa Hakko's Interest in Janssen Kyowa
November 5, 2001
- PMS Is Important for Products Approved via Bridging Studies: PMDEC
November 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
November 5, 2001
- Drug Classification Table for Selection of Comparator Drugs Approved by Chuikyo
November 5, 2001
- Yutaka Pharmacy Ties Up with Drug Lion, Reaching Sales of \50 Bil.
November 5, 2001
- Reduction in Price Adjustment Zone Below 2% Is Inappropriate: Korosho Director
November 5, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…